Related Experiment Video
Updated: Jun 2, 2026
09:44
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
New pathogenic paradigms in inflammatory bowel disease
Antonio Di Sabatino1, Paolo Biancheri, Laura Rovedatti
1First Department of Medicine, Centro per Studio e Cura delle Malattie Infiammatorie Croniche Intestinali, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy. a.disabatino@smatteo.pv.it
Inflammatory Bowel Diseases
|May 4, 2011
Summary
Recent advances reveal new causes of inflammatory bowel disease (IBD). The focus has shifted beyond T helper cells (Th1/Th2) to include Th17 cells, innate immunity, and dynamic inflammation, revealing novel therapeutic targets for IBD.
Area of Science:
- Immunology
- Gastroenterology
- Cell Biology
Background:
- The traditional T helper cell type (Th)1/Th2 paradigm is insufficient for understanding inflammatory bowel disease (IBD) pathogenesis.
- Emerging research highlights the critical role of T helper 17 (Th17) cells in IBD.
- Innate immunity, nonimmune cells, and tolerogenic mechanisms are increasingly recognized as key factors in IBD.
Purpose of the Study:
- To review recent scientific advancements that have reshaped the understanding of IBD pathogenesis.
- To discuss the evolving paradigms in IBD research, moving beyond adaptive immunity.
- To identify novel therapeutic targets based on new pathogenic insights in IBD.
Main Methods:
- Literature review of recent basic science progresses in IBD.
- Analysis of the role of T helper cell subsets, including Th17 cells.
- Evaluation of the contribution of innate immunity and nonimmune cells.
Main Results:
- The Th1/Th2 model is outdated; Th17 cells are crucial in IBD.
- Innate immunity and nonimmune cells significantly contribute to IBD.
- Intestinal inflammation is a dynamic process, not static.
Conclusions:
- New pathogenic mechanisms in IBD involve Th17 cells, innate immunity, and nonimmune cells.
- A dynamic view of intestinal inflammation reveals new therapeutic strategies.
- These evolving paradigms offer promising new targets for IBD treatment.
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:26Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...